ScoreWhy is Henan Lingrui Pharmaceutical Co., Ltd. ?
1
Poor long term growth as Net Sales has grown by an annual rate of 11.30% and Operating profit at 20.53% over the last 5 years
2
Negative results in Sep 25
- INTEREST COVERAGE RATIO(Q) Lowest at 11,174.79
- DEBT-EQUITY RATIO (HY) Highest at -8.01 %
- INVENTORY TURNOVER RATIO(HY) Lowest at 1.82 times
3
With ROE of 25.60%, it has a attractive valuation with a 4.11 Price to Book Value
- Over the past year, while the stock has generated a return of 4.97%, its profits have risen by 17.8% ; the PEG ratio of the company is 0.7
- At the current price, the company has a high dividend yield of 4
4
Underperformed the market in the last 1 year
- The stock has generated a return of 4.97% in the last 1 year, much lower than market (China Shanghai Composite) returns of 22.49%
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Henan Lingrui Pharmaceutical Co., Ltd. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Henan Lingrui Pharmaceutical Co., Ltd. for you?
Low Risk, Low Return
Absolute
Risk Adjusted
Volatility
Henan Lingrui Pharmaceutical Co., Ltd.
-12.43%
-0.59
20.95%
China Shanghai Composite
21.43%
1.58
14.20%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
10.25%
EBIT Growth (5y)
22.12%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.15
Sales to Capital Employed (avg)
1.09
Tax Ratio
12.98%
Dividend Payout Ratio
82.09%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
29.45%
ROE (avg)
18.32%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
15
Industry P/E
Price to Book Value
3.35
EV to EBIT
13.98
EV to EBITDA
12.80
EV to Capital Employed
3.69
EV to Sales
2.97
PEG Ratio
2.34
Dividend Yield
4.18%
ROCE (Latest)
26.41%
ROE (Latest)
21.89%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend2What is working for the Company
RAW MATERIAL COST(Y)
Fallen by -2.91% (YoY
NET SALES(Q)
Highest at CNY 1,126.07 MM
-11What is not working for the Company
INTEREST(HY)
At CNY 1.4 MM has Grown at 177.21%
OPERATING CASH FLOW(Y)
Lowest at CNY 737.33 MM
CASH AND EQV(HY)
Lowest at CNY 1,834.55 MM
Here's what is working for Henan Lingrui Pharmaceutical Co., Ltd.
Net Sales
Highest at CNY 1,126.07 MM
in the last five periodsMOJO Watch
Near term sales trend is positive
Net Sales (CNY MM)
Raw Material Cost
Fallen by -2.91% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Henan Lingrui Pharmaceutical Co., Ltd.
Interest
At CNY 1.4 MM has Grown at 177.21%
over previous Semi-Annual periodMOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (CNY MM)
Operating Cash Flow
Lowest at CNY 737.33 MM
in the last three yearsMOJO Watch
The company's cash revenues from business operations are falling
Operating Cash Flows (CNY MM)
Cash and Eqv
Lowest at CNY 1,834.55 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
